Value of Emerging and Existing Pre-prophylaxis and Therapeutic Options for COVID-19 in Transplant Recipients: A Systematic Review of Economic Evaluations
Cost effectiveness varied widely across studies due to differences in variant periods, population risk profiles, model assumptions, and healthcare systems. Future research should integrate variant-specific effectiveness, real-world vaccine responsiveness, long-term COVID-19 outcomes, and adverse events to better inform resource allocation for transplant and other high-risk populations.
Authors
- Caroline C. Piotrowski (ORCID: https://orcid.org/0000-0002-5752-6535)
- Geetha Sanmugalingham (ORCID: https://orcid.org/0000-0002-4279-1723)
- Dima Kabbani (ORCID: https://orcid.org/0000-0003-3785-1098)
- Alyssa Grant (ORCID: https://orcid.org/0000-0003-3374-5212)
- A. Hsu
- Kednapa Thavorn
- Patricia Gongal
- Rienk de Vries
- Andrew Vuong
- Sherrie Logan
- Becky Skidmore
Institutions
- Manitoba Health (CA)
- University of Ottawa (CA)
- University of Alberta (CA)
- University of Toronto (CA)
- Ottawa Hospital (CA)
- Translational Research in Oncology (CA)
- Ottawa Public Health (CA)
- Bruyère (CA)
- University of Manitoba (CA)
Publication Details
- Journal
- PharmacoEconomics - Open
- Published
- 2026-01-29
- DOI
- https://doi.org/10.1007/s41669-026-00639-w
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00